Literature DB >> 26041300

Broadly Neutralizing Human Immunodeficiency Virus Type 1 Antibody Gene Transfer Protects Nonhuman Primates from Mucosal Simian-Human Immunodeficiency Virus Infection.

Kevin O Saunders, Lingshu Wang, M Gordon Joyce, Zhi-Yong Yang, Alejandro B Balazs, Cheng Cheng, Sung-Youl Ko, Wing-Pui Kong, Rebecca S Rudicell, Ivelin S Georgiev, Lijie Duan, Kathryn E Foulds, Mitzi Donaldson, Ling Xu, Stephen D Schmidt, John-Paul Todd, David Baltimore, Mario Roederer, Ashley T Haase, Peter D Kwong, Srinivas S Rao, John R Mascola, Gary J Nabel.   

Abstract

Broadly neutralizing antibodies (bnAbs) can prevent lentiviral infection in nonhuman primates and may slow the spread of human immunodeficiency virus type 1 (HIV-1). Although protection by passive transfer of human bnAbs has been demonstrated in monkeys, durable expression is essential for its broader use in humans. Gene-based expression of bnAbs provides a potential solution to this problem, although immune responses to the viral vector or to the antibody may limit its durability and efficacy. Here, we delivered an adeno-associated viral vector encoding a simianized form of a CD4bs bnAb, VRC07, and evaluated its immunogenicity and protective efficacy. The expressed antibody circulated in macaques for 16 weeks at levels up to 66 g/ml, although immune suppression with cyclosporine (CsA) was needed to sustain expression. Gene-delivered simian VRC07 protected against simian-human immunodeficiency virus (SHIV) infection in monkeys 5.5 weeks after treatment. Gene transfer of an anti-HIV antibody can therefore protect against infection by viruses that cause AIDS in primates when the host immune responses are controlled.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26041300      PMCID: PMC4524228          DOI: 10.1128/JVI.00908-15

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  58 in total

1.  An antibody delivery system for regulated expression of therapeutic levels of monoclonal antibodies in vivo.

Authors:  Jianmin Fang; Saili Yi; Andrew Simmons; Guang Huan Tu; Minh Nguyen; Thomas C Harding; Melinda VanRoey; Karin Jooss
Journal:  Mol Ther       Date:  2007-03-20       Impact factor: 11.454

2.  Broad HIV-1 neutralization mediated by CD4-binding site antibodies.

Authors:  Yuxing Li; Stephen A Migueles; Brent Welcher; Krisha Svehla; Adhuna Phogat; Mark K Louder; Xueling Wu; George M Shaw; Mark Connors; Richard T Wyatt; John R Mascola
Journal:  Nat Med       Date:  2007-08-26       Impact factor: 53.440

3.  Stable antibody expression at therapeutic levels using the 2A peptide.

Authors:  Jianmin Fang; Jing-Jing Qian; Saili Yi; Thomas C Harding; Guang Huan Tu; Melinda VanRoey; Karin Jooss
Journal:  Nat Biotechnol       Date:  2005-04-17       Impact factor: 54.908

Review 4.  Immunogenicity of engineered antibodies.

Authors:  William Ying Khee Hwang; Jefferson Foote
Journal:  Methods       Date:  2005-05       Impact factor: 3.608

5.  Heparin binding directs activation of T cells against adeno-associated virus serotype 2 capsid.

Authors:  Luk H Vandenberghe; Lili Wang; Suryanarayan Somanathan; Yan Zhi; Joanita Figueredo; Roberto Calcedo; Julio Sanmiguel; Ravi A Desai; Christopher S Chen; Julie Johnston; Rebecca L Grant; Guangping Gao; James M Wilson
Journal:  Nat Med       Date:  2006-07-16       Impact factor: 53.440

6.  Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vector.

Authors:  R W Herzog; E Y Yang; L B Couto; J N Hagstrom; D Elwell; P A Fields; M Burton; D A Bellinger; M S Read; K M Brinkhous; G M Podsakoff; T C Nichols; G J Kurtzman; K A High
Journal:  Nat Med       Date:  1999-01       Impact factor: 53.440

7.  Frequency and phenotype of human immunodeficiency virus envelope-specific B cells from patients with broadly cross-neutralizing antibodies.

Authors:  Nicole A Doria-Rose; Rachel M Klein; Maura M Manion; Sijy O'Dell; Adhuna Phogat; Bimal Chakrabarti; Claire W Hallahan; Stephen A Migueles; Jens Wrammert; Rafi Ahmed; Martha Nason; Richard T Wyatt; John R Mascola; Mark Connors
Journal:  J Virol       Date:  2008-10-15       Impact factor: 5.103

Review 8.  Passive immunization as tool to identify protective HIV-1 Env epitopes.

Authors:  Victor G Kramer; Nagadenahalli B Siddappa; Ruth M Ruprecht
Journal:  Curr HIV Res       Date:  2007-11       Impact factor: 1.581

9.  Passive immunization with human neutralizing monoclonal antibodies against HIV-1 in macaque models: experimental approaches.

Authors:  Ruth M Ruprecht
Journal:  Methods Mol Biol       Date:  2009

10.  Vector-mediated gene transfer engenders long-lived neutralizing activity and protection against SIV infection in monkeys.

Authors:  Philip R Johnson; Bruce C Schnepp; Jianchao Zhang; Mary J Connell; Sean M Greene; Eloisa Yuste; Ronald C Desrosiers; K Reed Clark
Journal:  Nat Med       Date:  2009-05-17       Impact factor: 53.440

View more
  61 in total

Review 1.  Broadly Neutralizing Antibodies to HIV and Their Role in Vaccine Design.

Authors:  Dennis R Burton; Lars Hangartner
Journal:  Annu Rev Immunol       Date:  2016-05-20       Impact factor: 28.527

2.  Adeno-Associated Virus Delivery of Anti-HIV Monoclonal Antibodies Can Drive Long-Term Virologic Suppression.

Authors:  José M Martinez-Navio; Sebastian P Fuchs; Shara N Pantry; William A Lauer; Natasha N Duggan; Brandon F Keele; Eva G Rakasz; Guangping Gao; Jeffrey D Lifson; Ronald C Desrosiers
Journal:  Immunity       Date:  2019-03-05       Impact factor: 31.745

Review 3.  mRNA: A Novel Avenue to Antibody Therapy?

Authors:  Thomas Schlake; Moritz Thran; Katja Fiedler; Regina Heidenreich; Benjamin Petsch; Mariola Fotin-Mleczek
Journal:  Mol Ther       Date:  2019-03-06       Impact factor: 11.454

4.  Use of a gamma-2 herpesvirus as a vector to deliver antibodies to rhesus monkeys.

Authors:  G F Bischof; Y C Shin; S P Fuchs; J M Martinez-Navio; W A Lauer; E G Rakasz; R C Desrosiers
Journal:  Gene Ther       Date:  2017-06-29       Impact factor: 5.250

5.  SIV infection duration largely determines broadening of neutralizing antibody response in macaques.

Authors:  Fan Wu; Ilnour Ourmanov; Andrea Kirmaier; Sivan Leviyang; Celia LaBranche; Jinghe Huang; Sonya Whitted; Kenta Matsuda; David Montefiori; Vanessa M Hirsch
Journal:  J Clin Invest       Date:  2020-10-01       Impact factor: 14.808

6.  In vivo delivery of synthetic DNA-encoded antibodies induces broad HIV-1-neutralizing activity.

Authors:  Megan C Wise; Ziyang Xu; Edgar Tello-Ruiz; Charles Beck; Aspen Trautz; Ami Patel; Sarah Tc Elliott; Neethu Chokkalingam; Sophie Kim; Melissa G Kerkau; Kar Muthumani; Jingjing Jiang; Paul D Fisher; Stephany J Ramos; Trevor Rf Smith; Janess Mendoza; Kate E Broderick; David C Montefiori; Guido Ferrari; Daniel W Kulp; Laurent M Humeau; David B Weiner
Journal:  J Clin Invest       Date:  2020-02-03       Impact factor: 14.808

Review 7.  Multi-Envelope HIV-1 Vaccine Development: Two Targeted Immune Pathways, One Desired Protective Outcome.

Authors:  Julia L Hurwitz; Mattia Bonsignori
Journal:  Viral Immunol       Date:  2018-01-09       Impact factor: 2.257

Review 8.  Survivors Remorse: antibody-mediated protection against HIV-1.

Authors:  George K Lewis; Marzena Pazgier; Anthony L DeVico
Journal:  Immunol Rev       Date:  2017-01       Impact factor: 12.988

9.  Identification of Novel Structural Determinants in MW965 Env That Regulate the Neutralization Phenotype and Conformational Masking Potential of Primary HIV-1 Isolates.

Authors:  Zakiya M Qualls; Alok Choudhary; William Honnen; Raja Prattipati; James E Robinson; Abraham Pinter
Journal:  J Virol       Date:  2018-02-12       Impact factor: 5.103

10.  Differential induction of anti-V3 crown antibodies with cradle- and ladle-binding modes in response to HIV-1 envelope vaccination.

Authors:  Preetha Balasubramanian; Rajnish Kumar; Constance Williams; Vincenza Itri; Shixia Wang; Shan Lu; Ann J Hessell; Nancy L Haigwood; Faruk Sinangil; Keith W Higgins; Lily Liu; Liuzhe Li; Phillipe Nyambi; Miroslaw K Gorny; Maxim Totrov; Arthur Nadas; Xiang-Peng Kong; Susan Zolla-Pazner; Catarina E Hioe
Journal:  Vaccine       Date:  2017-02-06       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.